It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Polycomb group (PcG) proteins are known to repress developmental genes during embryonic development and tissue homeostasis. Here, we report that PCGF6 controls neuroectoderm specification of human pluripotent stem cells (PSCs) by activating SOX2 gene. Human PSCs with PCGF6 depletion display impaired neuroectoderm differentiation coupled with increased mesendoderm outcomes. Transcriptome analysis reveals that de-repression of the WNT/β-catenin signaling pathway is responsible for the differentiation of PSC toward the mesendodermal lineage. Interestingly, PCGF6 and MYC directly interact and co-occupy a distal regulatory element of SOX2 to activate SOX2 expression, which likely accounts for the regulation in neuroectoderm differentiation. Supporting this notion, genomic deletion of the SOX2-regulatory element phenocopies the impaired neuroectoderm differentiation, while overexpressing SOX2 rescues the neuroectoderm phenotype caused by PCGF6-depletion. Together, our study reveals that PCGF6 can function as lineage switcher between mesendoderm and neuroectoderm in human PSCs by both suppression and activation mechanisms.
Variant Polycomb complexes can have tissue-specific roles during development. Here they show that PCGF6 controls lineage-specification in human PSCs by promoting neuroectoderm differentiation and repressing mesendoderm differentiation via distinct downstream targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Zhang, Tianzhe 1 ; Yi, Ying 1 ; Li, Conghui 2 ; Jin, Wenwen 1 ; Chen, Jian 3 ; Liang, Kaiwei 2 ; Wang, Hengbin 4
; Jiang, Wei 5
1 Wuhan University, Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, RNA Institute, Zhongnan Hospital of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
2 Wuhan University, Department of Pathophysiology, School of Basic Medical Sciences, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
3 Chinese Academy of Medical Sciences, Chinese Institute for Brain Research (Beijing), Research Unit of Medical Neurobiology, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
4 Virginia Commonwealth University, Department of Internal Medicine, Division of Hematology, Oncology, and Palliative Care, Massey Cancer Center, Richmond, USA (GRID:grid.224260.0) (ISNI:0000 0004 0458 8737)
5 Wuhan University, Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, RNA Institute, Zhongnan Hospital of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Human Genetics Resource Preservation Center of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)




